Antiretroviral Agents in HIV-1 (2014)

DHHS Adult HIV 2014

DHHS HIV GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/282343

Contents of this Issue

Navigation

Page 11 of 23

Selecting a Treatment Regimen Table 5. Laboratory Monitoring Schedule for HIV-Infected Patients Before and After Initiation of Antiretroviral Therapy a (continued) Laboratory Test Timepoint/Frequency of Testing Entry into Care Follow Up Before Initiation of ART ART Initiation or Modification b Follow-Up 2-8 Weeks After ART Initiation or Modification Hepatitis C Serology, with Confirmation of Positive Results Basic Chemistry g,h Every 6-12 mos ALT, AST, T. bilirubin Every 6-12 mos CBC with Differential Every 3-6 mos If on ZDV Fasting Lipid Profile If normal, annually Consider 4-8 wks aer starting new ART regimen that affects lipids Fasting Glucose or Hemoglobin A1C If normal, annually Urinalysis g Pregnancy Test In women with child-bearing potential a is table pertains to laboratory tests done to select an ARV regimen and monitor for treatment responses or ART toxicities. Please refer to the HIV Primary Care guidelines for guidance on other laboratory tests generally recommended for primary health care maintenance of HIV patients. (http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf ) b ART may be modified because of treatment failure, adverse effects, or for regimen simplification. c If HIV RNA is detectable at 2 to 8 weeks, repeat every 4 to 8 weeks until viral load is suppressed to <200 copies/mL, and thereaer, every 3 to 6 months. d In patients on ART, viral load typically is measured every 3 to 4 months. However, for adherent patients with consistently suppressed viral load and stable immunologic status for more than 2 years, monitoring can be extended to 6 month intervals. e In ART-naive patients, if resistance testing was performed at entry into care, repeat testing before initiation of ART is optional. e exception is pregnant women; repeat testing is recommended in this case. In virologically suppressed patients who are switching therapy because of toxicity or for convenience, viral amplification will not be possible. erefore, resistance testing should not be performed. Results from prior resistance testing can be helpful in constructing a new regimen. 10

Articles in this issue

Links on this page

Archives of this issue

view archives of Antiretroviral Agents in HIV-1 (2014) - DHHS Adult HIV 2014